PhD Student Ásta Milthers Theódórsdórttir Department of Neurology, Odense University Hospital
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Inkluderede deltagere med prøver
The Danish experience of alemtuzumab treatment in relapsing remitting multiple sclerosis: based on registry data
The overall objective of this study is to describe the effectiveness and safety of alemtuzumab in a population based real life setting. The study will include a sub-analysis of disease activity among patients receiving alemtuzumab early in the disease course as compared to escalation treatment in subjects with high disease activity. It is based on registerdata from the Danish Multiple Sclerosis Registry.
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody licensed for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Lemtrada® received EMA approval for treatment of MS in 2013 and since then 211 patients with highly active RRMS has been treated with alemtuzumab in Denmark. Among Danish MS neurologists there is a genereal perception, that during the last couple of years, alemtuzumab treatment has in general been initiated earlier in the patient's disease course as compared to the first couple of years after launch.
Description of the cohort
Included in the study are all relapsing-remitting multiple sclerosis patients where treatment with alemtuzumab was initiated since December 2013 until Jan 2019. These are adults, mixed men and women.
Data and biological material
Register data only.
Publications associated with the project
Department of Neurology, Odense University Hospital
Professor Zsolt Illes
Department of Public Health, Epidemiology, Biostatistics and Biodemography, University of Southern Denmark